Objective To explore the targets and signaling pathways of Sophorae Flavescentis Radix in treating atrial fibrillation, and decipher the possible mechanism based on network pharmacology.Methods The active ingredients and targets of Sophorae Flavescentis Radix were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform（TCMSP）and screened based on Absorption, Distribution, Metabolism, and Excretion（ADME）.The targets associated with atrial fibrillation were obtained from GeneCards and Online Mendelian Inheritance in Man（OMIM）.The common targets shared by Sophorae Flavescentis Radix and atrial fibrillation were taken as the targets involved in the treatment.A protein-protein interaction（PPI）network was built with the STRING database.Cytoscape 3.7.2 was used to build a component-target-pathway network.Bioconductor was used for Gene Ontology（GO）functional annotation and Kyoto Encyclopedia of Genes and Genomes（KEGG）pathway enrichment.CB-Dock was employed to carry out the molecular docking of the active ingredients of Sophorae Flavescentis Radix and ranolazine with SCN5A.Results The main targets were IL-6,AKT1,VEGFA,CASP3,JUN,MAPK1,PTGS2,MMP9,IL-1β,and SCN5A.Sophorae Flavescentis Radix mainly treated atrial fibrillation by regulating the AGE-RAGE,IL-17,and TNF signaling pathways.The molecular docking suggested that phaseolin, glyceollin, and luteolin had strong binding activities with SCN5A,with the Vina scores close to that of ranolazine.Conclusion Sophorae Flavescentis Radix may treat atrial fibrillation by suppressing atrial remodeling and myocardial apoptosis, mitigating inflammation, and interfering in cardiomyocyte ion channels.Our prediction provided references for revealing the mechanism of Sophorae Flavescentis Radix in the treatment of atrial fibrillation in the future.

目的 运用CiteSpace软件对心血管疾病组学研究进行文献计量可视化分析,探究组学在心血管疾病中的运用现状和研究热点.方法 检索Web of Science Core Collection数据库(WOSCC),将检索到有关心血管疾病组学研究的数据导入CiteSpace绘制知识图谱,对作者、机构、地区、关键词和共被引文献进行可视化分析.结果 心血管疾病组学研究有关文献发文量从2016年起呈爆发上升趋势.发文量靠前的作者有Matthias Schittmayer和Ruth Birnergruenberger等,国家有美国、德国、英国等,机构有哈佛医学院、格拉斯哥大学、华盛顿大学等.关键词分析显示研究热点集中于疾病风险、炎症、死亡率、肠道微生物群的研究.Nikpay M(2015)、Kundaje A(2015)、Wang TJ(2011)的3篇核心共被引文献为该领域研究的基础.结论 通过文献计量学分析,心血管病组学领域目前正处于研究高热期,但作者间合作较少.代谢组学和蛋白质组学运用较广且热度持续.组学应用于心血管疾病研究具有诊断、治疗、预测疾病风险等作用,可发现疾病本质并用于开发新的预防治疗策略.

真实世界中医临床科研范式的核心是临床科研一体化.中医临床一体化平台首先被开发出来,不同的平台或侧重科研或侧重辅助医院日常工作,随着时代发展和科技进步,中医临床科研大数据平台的概念被提出.目前,已有关于建设中医临床科研大数据平台的技术方法和架构设计的探讨.现有的平台或构想存在一定不足,基于此我们提出对中医临床科研大数据平台的构想和展望,平台以人工智能为技术支持、真实世界为数据管理方式、单病例随机对照试验为临床研究方法,可处理大量、来源不同的数据,同时可辅助临床决策,这样的平台可兼顾中医药循证医学特点和个体精准施治要求,既满足科研需求又能辅助临床决策.

目的 探讨盐敏感性高血压患者24 h收缩压负荷(24h SBPL)与肾素-血管紧张素-醛固酮系统(RAAS)成分及血清皮质醇(COR)之间的关联.方法 通过收纳2015年6月至2016年6月于中国中医科学院广安门医院心血管科符合盐敏感性高血压的住院患者,按照动态血压参数24h SBPL进行分组:收缩压负荷≥50％为高负荷组,<50％为低负荷组;测定患者RAAS系统中血清血管紧张素Ⅰ(AngⅠ)、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)及HPA轴系统血清皮质醇(COR),比较两组之间上述成分有无差异.结果 两组患者RASS系统中ALD水平高负荷组显著高于低负荷组,差异有统计学意义(P<0.05).两组患者24h SBPL分别与ALD成正相关(r=0.310,P<0.001),与COR成正相关(r=0.556,P<0.001).结论 盐敏感高血压患者收缩压负荷可能与ALD及COR存在一定相关性.

趋化因子已成为各疾病领域研究的热点，通过借助PubMed、UniProtKB数据库归纳和完善了目前已知的趋化因子配体及其对应结合的受体、趋化因子的来源及主要趋化功效等；总结了趋化因子在冠状动脉粥样硬化性心脏病及心房颤动等心血管疾病中的研究进展。得出趋化因子配体或结合相关受体组成一定的信号通路发挥作用，涉及机制多集中在促炎、促纤维化、促动脉粥样硬化等方面。

目的 对钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)干预心力衰竭的相关文献进行可视化分析,探讨其研究进展与热点.方法 检索Web of Science Core Collection数据库(WOSCC),将检索到有关SGLT2i干预心力衰竭的数据导入Cite Space绘制知识图谱,对作者、机构、国家和关键词进行可视化分析.结果 SGLT2i干预心力衰竭的有关文献发文量从2016年起呈逐年上升趋势.发文量靠前的作者有Silvio E Inzucchi,Subodh Verma,Darren K Mcguire等,国家有美国、英国、加拿大等,机构有多伦多大学、哈佛医学院、哈佛大学医学院附属布列根和妇女医院等.关键词分析得出二肽基肽酶4抑制剂(DPP-4i)和SGLT2i、EMPA-REG OUTCOME研究,胰高血糖素样肽-1受体激动剂(GLP-1RA)和心血管死亡率预后等为研究热点.结论 通过文献计量学分析,SGLT2i干预心力衰竭领域目前正处于研究高热期,但发文量不多,需继续完善相关研究,加强各个国家和机构的合作.研究热点更新较快,研究有很大的发展空间.

Takotsubo cardiomyopathy (TTC) is often acute with a high mortality rate and is subject to relapse. Meanwhile, its complex pathogenesis has attracted increasing attention. To learn more about TTC, CiteSpace V.5.7 R5W was used in this study to analyze the research status, hot spots, and trends in TTC before 2020. The keywords, co-citation references, as well as country and institution distribution were explored. A total of 2,349 papers were reviewed. The United States, Italy, and Germany were the main countries studying TTC and had good cooperation relationships. The Mayo Clinic topped the institution list, but the rate of inter-institutional cooperation was not high. Research hotspots include disease features, auxiliary diagnostic methods, epidemiology, and pathophysiological mechanisms, and the latest ones are complications related to prognosis, such as cardiovascular abnormalities caused by myocardial infarction and normal or non-obstructive coronary arteries (MINOCA), atrial fibrillation, stroke, cancer, and COVID-19. In conclusion, the research of TTC is in a hot development period. Our research will help clinicians and researchers to better understand TTC and its research status by providing a foundation for research objectives. In doing this, our research will help to provide better scientific management, diagnosis, and treatment for patients with TTC, which will in turn improve the prognosis of this condition.

目的 探索外周血不同大小微粒的绝对数量对冠心病及冠心病血瘀证发生的诊断价值.方法 选取冠心病患者120例,根据血瘀证辨证标准分为血瘀证组55例及非血瘀证组65例,另设健康志愿者31例作为健康组.各组受试者利用梯度离心法分离人外周血微粒,并通过0.46 μm及1.0μm微球在流式细胞仪上圈定大微粒及小微粒位置,以Annexin V+(AV+)作为微粒的确定标准,采用绝对计数法统计大微粒、小微粒绝对数量.以大微粒、小微粒为自变量,以冠心病及冠心病血瘀证为因变量进行单因素分析及Logistic多因素回归分析,并绘制受试者操作特征(ROC)曲线图评估大微粒、小微粒对冠心病的诊断效能.结果 血瘀证组和非血瘀证组患者外周血大微粒、小微粒绝对数量均高于健康组(P＜0.05或P＜0.01);血瘀证组患者外周血大微粒、小微粒绝对数量均高于非血瘀证组(P＜0.05或P＜0.01).单因素相关性分析显示,大微粒与冠心病血瘀证的发生相关(r=0.291,P=0.001);小微粒与冠心病血瘀证的发生相关(r=0.191,P=0.036).Logistic多因素回归分析结果显示,大微粒与冠心病(回归系数:0.008,P＜0.05)及冠心病血瘀证(回归系数:0.003,P＜0.05)的发生相关,小微粒与冠心病(回归系数:0.006,P=0.039)及冠心病血瘀证(回归系数:0.004,P＜0.05)的发生相关.ROC分析结果显示,大微粒的ROC曲线下面积(AUC)值为0.777,95％CI:0.702～0.852,P=0.001;小微粒的 AUC 值为0.676,95％CI:0.576～0.776,P=0.003.结论 外周血大微粒和小微粒的绝对数量均与冠心病及冠心病血瘀证的发生相关,其中大微粒的绝对数量对冠心病有一定的诊断价值.

目的:对有关穿心莲的文献进行可视化分析,研究其近20年来的热点及进展过程.方法:以中国知网(CNKI)为来源数据库,检索以穿心莲为主题的文献,运用可视化文献分析软件(CiteSpace)V和CNKI自带的计量可视化分析工具进行文献数、作者、机构和关键词的共现分析及可视化表达.结果:研究穿心莲的主要人员有韩光、万遂如、何瑞、张文成、杜红、詹若挺、徐海伟、潘见等;主要机构有广州中医药大学、河南大学、广东药科大学、成都中医药大学、华中科技大学、北京中医药大学等;主要研究方向有抗感染、糖尿病、心血管疾病、抗肿瘤、保肝、质控方法等.近年来受到关注较多的研究热点是细胞凋亡、生物膜、核因子κB(NF-κB)信号通路、糖尿病.结论:研究穿心莲的学术团队局限在各机构中,而各研究机构之间合作较少;细胞凋亡、生物膜、NF-κB、糖尿病将继续成为研究热点.

The crosstalk between the heart and kidney is carried out through various bidirectional pathways. Cardiorenal syndrome (CRS) is a pathological condition in which acute or chronic dysfunction in the heart or kidneys induces acute or chronic dysfunction of the other organ. Complex hemodynamic factors and biochemical and hormonal pathways contribute to the development of CRS. In addition to playing a critical role in generating metabolic energy in eukaryotic cells and serving as signaling hubs during several vital processes, mitochondria rapidly sense and respond to a wide range of stress stimuli in the external environment. Impaired adaptive responses ultimately lead to mitochondrial dysfunction, inducing cell death and tissue damage. Subsequently, these changes result in organ failure and trigger a vicious cycle. In vitro and animal studies have identified an important role of mitochondrial dysfunction in heart failure (HF) and chronic kidney disease (CKD). Maintaining mitochondrial homeostasis may be a promising therapeutic strategy to interrupt the vicious cycle between HF and acute kidney injury (AKI)/CKD. In this review, we hypothesize that mitochondrial dysfunction may also play a central role in the development and progression of CRS. We first focus on the role of mitochondrial dysfunction in the pathophysiology of HF and AKI/CKD, then discuss the current research evidence supporting that mitochondrial dysfunction is involved in various types of CRS.

Background The global community has been affected by the coronavirus disease 2019 (COVID-19), which emerged in December 2019. Since then, many studies have been conducted on cardiovascular diseases (CVDs) and COVID-19. The aim of this study was to perform a bibliometric and visual analysis of the published relationship between CVDs and COVID-19. Methods 1,890 publications were retrieved from the Web of Science Core Collection database on January 5, 2022. Microsoft Office Excel and CiteSpace were then used to carry out scientometric analysis on the relevant literature according to seven aspects: document type, countries/regions, institutions, authors, journals, references, and keywords. Results The research on CVDs and COVID-19 is currently in a period of rapid development, with China, USA, England, and Italy leading the field. There is active cooperation between most countries and institutions. Harvard Medical School stands out among the many institutions not only for the largest number of publications, but also for their high quality. Banerjee A, Solomon SD and Narula J are three representative authors in this field. Frontiers in Cardiovascular Medicine was the journal with the highest number of published studies, and The Lancet was the most cited journal. Two documents with a high degree of significance in this field were identified. Popular research topics in this field are specific diseases, such as acute coronary syndrome and heart failure; pathogenesis related to ACE2, insulin resistance and pericyte; the specific therapeutic drug chloroquine; and clinical characteristics, physical activity, and mental health. ACE2 and NF-κB will be the focus of future research. Conclusions This study provides useful information for the research of CVDs and COVID-19, including potential collaborators, popular research topics, and a reference for more extensive and in-depth research in the future.

Background: Homozygous familial hypercholesterolaemia (HoFH) patients have little or no low-density lipoprotein receptor (LDLR) function. HMG-CoA (3-hydroxy-3-methyl glutaryl coenzyme A) reductase inhibitors (statins) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have limited lipid-lowering effects, therefore, there is an urgent need to develop new HoFH treatments. In 2012, the US Food and Drug Administration (FDA) approved the administration of lomitapide for lowering low-density lipoprotein cholesterol (LDL-C) levels. However, lomitapide is associated with various gastrointestinal disorders, elevated hepatic alanine aminotransferase (ALT) levels and other adverse reactions, thus, its long-term efficacy and safety in pediatrics and adults should be evaluated. A systematic review conducted in 2017 reported the efficacy and safety of lomitapide in Family hypercholesterolaemia (FH) patients. In this systematic review, we elucidate on the efficacy and safety of lomitapide in HoFH patients. Methods: A search was conducted in PubMed, Embase, Web of Science and Cochrane library databases to identify valid studies involving lomitapide-treated HoFH patients published before 11th August 2021. Results: A total of 18 clinical studies involving 120 lomitapide-treated HoFH patients were identified. Lomitapide significantly suppressed LDL-C levels in HoFH patients. Clinical manifestations for lomitapide in children were comparable to those in adults. The most common adverse events were gastrointestinal disturbances and elevated ALT levels. However, most patients tolerated the treatment-associated adverse reactions. Low-fat diets and drug dose adjustments were appropriate measures for controlling the treatment-associated adverse reactions. Conclusions: In pediatric and adult HoFH patients, lomitapide significantly suppresses LDL-C levels, therefore, it is an important option for HoFH treatment. The most common adverse events of lomitapide treatment include gastrointestinal disorders and elevated hepatic ALT levels. Despite the limitations, lomitapide is feasible for long-term treatment of HoFH patients, with dietary and safety monitoring. Registration Number in PROSPERO: CRD42021284425.

Ulcerative colitis (UC) is a disease with complex pathological mechanisms. We explored the potential molecular mechanisms behind the therapeutic functions of Qingzi Zhitong decoction (QZZTD) in the treatment of UC by network pharmacology and molecular docking. QZZTD is a formula of Chinese traditional medicine consisting of 10 herbs. The potential active ingredients of QZZTD and their target genes were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database, and UC-related target genes were obtained from GeneCards and OMIM databases. A total of 138 co-identified target genes were obtained by plotting the intersection target Venn diagram, and then the STRING database and Cytoscape software were used to establish protein-protein interaction networks and herb-ingredient-target networks. Four key active compounds and nine key proteins were identified. Then, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses showed that the biological functions of potential target genes were associated with DNA transcription, signaling receptor and ligand activity, cytokine activity, cellular autophagy, and antioxidant pathways, with related pathways involving the phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway, advanced glycosylation end product (AGE)-RAGE signaling pathway, tumor necrosis factor (TNF) signaling pathway, and IL-17 signaling pathway. Moreover, the binding activities of key target genes and essential active compounds of Chinese herbal medicines in QZZTD were further validated by molecular docking. This demonstrated that quercetin, luteolin, hyndarin, and beta-sitosterol had good binding to eight key proteins, and Akt1 was the target protein with the best binding activity, suggesting that Akt1 could be the essential mediator responsible for signaling transduction after QZZTD administration. The rat experiment verified that QZZTD inhibited PI3K-Akt pathway activation and reduced inflammation in UC. In conclusion, our study suggested four potential key active components, including quercetin, were identified in QZZTD, which could interact with Akt1 and modulate the activation of the PI3K-Akt pathway. The other three pathways may also be involved in the signaling transduction induced by QZZTD in the treatment of UC.

Abstract Background: Atrial fibrillation (AF) is one of the most common arrhythmias, and is high relative to cardiovascular morbidity and mortality. AF-related complications and treatment costs bring about huge health burden, therefore the prevention recurrence of AF is imperative. “Upstream therapy” refers to the use of non-antiarrhythmic drugs (non-AADs) that modify the atrial substrate or target-specific mechanisms of AF to prevent the occurrence or recurrence of the arrhythmia. RAAS Blockers, aldosterone receptor antagonists and statins have an effect on preventing recurrence of atrial fibrillation. This protocol is designed for systematic review and network meta-analysis, which will assess comparative effects and safety of various non-antiarrhythmic drugs in preventing recurrence of atrial fibrillation. Methods: The Cochrane Library, MEDLINE, EMBASE, ClinicalTrials.gov will be searched from inception to Aug 31, 2020 to identify relevant studies. The Cochrane “Risk of bias” tool will be used to assess the methodological quality of eligible studies. The pair-wise meta-analysis will be performed by STATA 14.0 software. The network meta-analysis will be implemented in a Bayesian framework using Win BUGS 1.4.3 and the package “gemtc” V.0.8.1 of R-3.6.2 software. The network plots will be drawn using STATA 14.0 software. A comparison-adjusted funnel plot will be used to assess the publication bias using STATA 14.0 software. Quality of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: The results of this network meta-analysis will determine the preventive effect and rank ordering of these interventions for recurrence of AF. The report will follow the PRISMA checklist for network meta-analysis. Conclusion: This network meta-analysis will provide comprehensive evidence-based information in clinical practice. Inplasy registration number: INPLASY202090004.

Background: Atrial fibrillation (AF) is one of the most common arrhythmias, and is high relative to cardiovascular morbidity and mortality. AF-related complications and treatment costs bring about huge health burden, therefore the prevention recurrence of AF is imperative. "Upstream therapy" refers to the use of non-antiarrhythmic drugs (non-AADs) that modify the atrial substrate or target-specific mechanisms of AF to prevent the occurrence or recurrence of the arrhythmia. RAAS Blockers, aldosterone receptor antagonists and statins have an effect on preventing recurrence of atrial fibrillation. This protocol is designed for systematic review and network meta-analysis, which will assess comparative effects and safety of various non-antiarrhythmic drugs in preventing recurrence of atrial fibrillation. Methods: The Cochrane Library, MEDLINE, EMBASE, ClinicalTrials.gov will be searched from inception to Aug 31, 2020 to identify relevant studies. The Cochrane "Risk of bias" tool will be used to assess the methodological quality of eligible studies. The pair-wise meta-analysis will be performed by STATA 14.0 software. The network meta-analysis will be implemented in a Bayesian framework using Win BUGS 1.4.3 and the package "gemtc" V.0.8.1 of R-3.6.2 software. The network plots will be drawn using STATA 14.0 software. A comparison-adjusted funnel plot will be used to assess the publication bias using STATA 14.0 software. Quality of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: The results of this network meta-analysis will determine the preventive effect and rank ordering of these interventions for recurrence of AF. The report will follow the PRISMA checklist for network meta-analysis. Conclusion: This network meta-analysis will provide comprehensive evidence-based information in clinical practice. Inplasy registration number: INPLASY202090004.

Background: The combination of Chinese patent medicine Wenxin Granules (WXG) and antiarrhythmic drugs has been widely used in the treatment of atrial fibrillation (AF), but the results are controversial. This study will conduct a network meta-analysis (NMA) based on data from randomized controlled trials to evaluate the efficacy and safety of WXG combined with ADDs (amiodarone, metoprolol, propafenone, bisoprolol, or other antiarrhythmic drugs) in the treatment of AF, which will perform comparisons or rankings of efficacy among the currently available therapeutic schemes in order to provide evidence to determine the optimal threshold and treatment regimen to AF patients. Methods and analysis: A comprehensive systematic literature search will be conducted in Cochrane Library, PubMed, Web of Science, EMBASE, Chinese Biomedical Literature Database (SinoMed), Chinese National Knowledge Infrastructure (CNKI), and WanFang database for randomized controlled trials about the WXG with ADDs. The NMA will be conducted following the PRISMA-NMA guidelines. Statistical analyses will be conducted by using Stata software (version 14.0) and RevMan software (version 5.3). Results: The results of this NMA will provide a high-quality evidence for the efficacy of WXG combined with ADDs in the treatment of AF, and a ranking of the therapeutic classes will also be presented. Conclusion: The protocol will provide updated evidence for the application of WXG for AF.

目的 借助CiteSpace软件对近15年肌少-骨质疏松症领域的研究现状、热点及趋势进行可视化分析.方法 以Web of Science核心合集数据库为搜索来源,利用CiteSpace V.5.6 R2可视化分析软件对近15年肌少-骨质疏松症的研究进行可视化分析,探讨相关研究的作者、国家/机构分布、期刊分布状况及对关键词进行可视化分析.结果 纳入459篇SCI文章,发文量最高的作者是GUSTAVO DUQUE,引文量最高的作者是Cruz-Jentoft AJ,美国和日本是研究肌少-骨质疏松症的主要国家,墨尔本大学和塔夫茨大学的中心性最高,是研究肌少-骨质疏松症的重要机构,被引频次最高的期刊是Osteoporosis Int,被引频次最多的文章作者是Cruz-Jentoft AJ,主要的研究热点是肌少症和骨质疏松症的诊断标准、肌少症与骨质疏松症的相关性及其防治方法.结论 本研究对现阶段肌少-骨质疏松症的研究进展提供了一系列总结和归纳,为研究者提供了有效的、可快速利用的有价值信息.

目的 对心房颤动气阴两虚证相关文献进行文献计量分析,探究心房颤动气阴两虚证相关研究领域的研究现状及研究热点.方法 以中国医院数字图书馆全文数据库为资料来源,利用数据库内置计量可视化功能对心房颤动气阴两虚证相关研究的年度发文量、机构、作者和关键词进行可视化分析.结果 共纳入文献145篇,年发文量总体呈现上升趋势.北京中医药大学是发文量最多的机构,辽宁中医药大学附属医院的张艳是心房颤动气阴两虚证相关研究中发文最多的作者.热点关键词有:对照组、临床疗效、治疗、中医证候、冠心病、临床研究、炙甘草汤、生脉散、胺碘酮、维拉帕米、左房内径.结论 心房颤动气阴两虚证的研究越来越受到学者的关注;在研究的合作方面,不同作者及机构间需要加强合作;研究的热点方向为心房颤动的中医证候及中医药治疗心房颤动的临床疗效的评价研究,涉及较多的方药是稳心颗粒、生脉散、炙甘草汤;常用的西医对照药物有胺碘酮和维拉帕米,研究较多的合并疾病为冠心病.

目的 评价红细胞分布宽度水平(RDW)与心房颤动(房颤)发生/复发关系.方法 利用计算机检索PubMed、EMbase、Web of Science等英文数据库,中国知网、维普、万方等中文数据库,检索日期为自建库至2018年12月,利用Revman5.3软件及Stata14.0软件对提取的数据进行Meta分析.结果 初步检索获得217篇文献,经筛选共纳入了9篇符合标准的文献,其中病例组720例,对照组1480例.Meta分析结果显示,房颤患者RDW水平高于非房颤患者,结果存在统计学意义(SMD=0.804,95％CI:0.439～1.169,P<0.01).亚组分析结果显示,RDW水平与房颤发生相关性因人种而异,在白种人中有统计学意义,在黄种人无统计学意义.术前RDW水平较高的冠状动脉搭桥术患者、射频消融术患者及冷冻消融术患者,术后更易复发房颤.研究中未发现有明显发表偏倚.结论 红细胞分布宽度是房颤发生/复发的独立预测因素.

Rapid increases in metabolic disorders, such as type 2 diabetes mellitus (T2DM) and hyperlipidemia, are becoming a substantial challenge to worldwide public health. Traditional Chinese medicine has a long history and abundant experience in the treatment of diabetes and hyperlipidemia, and Puerariae lobatae Radix (known as Gegen in Chinese) is one of the most prevalent Chinese herbs applied to treat these diseases. The underlying mechanism by which Gegen simultaneously treats diabetes and hyperlipidemia, however, has not been clearly elucidated to date. Therefore, we systematically explored the potential mechanism of Gegen in the treatment of T2DM complicated with hyperlipidemia based on network pharmacology. We screened the potential targets of Gegen, T2DM, and hyperlipidemia in several online databases. Then, the hub targets were analyzed by performing protein-protein interaction, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment assays, and finally, the complicated connections among compounds, targets, and pathways were visualized in Cytoscape. We found that isoflavones, including daidzein, genistein, and puerarin, as well as β-sitosterol, are the key active ingredients of Gegen responsible for its antidiabetic and antihyperlipidemia effects, which mainly target AKR1B1, EGFR, ESR, TNF, NOS3, MAPK3, PPAR, CYP19A1, INS, IL6, and SORD and multiple pathways, such as the PI3K-Akt signaling pathway; the AGE-RAGE signaling pathway in diabetic complications, fluid shear stress, and atherosclerosis; the PPAR signaling pathway; insulin resistance; the HIF-1 signaling pathway; the TNF signaling pathway; and others. These active ingredients also target multiple biological processes, including the regulation of glucose and lipid metabolism, the maintenance of metabolic homeostasis, and anti-inflammatory and antioxidant pathways. In conclusion, Gegen is a promising therapeutic phytomedicine for T2DM with hyperlipidemia that targets multiple proteins, biological processes, and pathways.